← Back to Search

Metabolic Imaging for Glioblastoma

Q: Is enrollment for this trial currently accepting participants?

<p>Affirmative. The details available on clinicaltrials.gov point to this clinical trial actively recruiting candidates, which was initially registered on September 6th of 2023 and recently updated on October 24th of the same year. As such, it is looking for 50 participants from a single medical centre.</p>

Q: Are there a substantial number of participants involved in the trial?

<p>Affirmative. Research hosted on clinicaltrials.gov verifies that this research trial, first posted in September 6th 2023, is currently enrolling applicants. A total of 50 patients need to be signed up from one medical centre.</p>

Phase 1 & 2

Recruiting

Led By Benjamin Ellingson, PhD

Research Sponsored by Jonsson Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age > 18

Patients with newly diagnosed or recurrent glioblastoma clinically indicated for resective surgery

Timeline

Screening 3 weeks

Treatment Varies

Follow Up two years

Awards & highlights

Study Summary

This trial tests a new imaging technique to measure glycolysis in brain tumors. Measures of pH, RNA, proteins, and enzymes will be taken and compared.

Who is the study for?

This trial is for adults over 18 with new or returning glioblastoma who are scheduled for tumor removal surgery. It's not suitable for those unable to undergo MRI or PET scans, have metal implants that could be hazardous in scans, have severe kidney issues (GFR < 30), or extreme claustrophobia.Check my eligibility

What is being tested?

The study is testing a novel imaging technique combining MRI and PET to measure glycolysis in brain tumors. Researchers will compare images with actual tissue samples from surgeries to see how well the imaging reflects tumor metabolism.See study design

What are the potential side effects?

Since this trial involves standard imaging procedures and biopsies already planned as part of treatment, side effects may include typical risks associated with these processes such as discomfort at biopsy site, allergic reactions to contrast agents used in scans, and potential complications from sedation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 18 years.

Select...

I have a new or returning glioblastoma and need surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ two years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~two years

This trial's timeline: 3 weeks for screening, Varies for treatment, and two years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Glycolytic Index

Immunohistochemistry Expression of Glycolytic Molecules

Trial Design

1Treatment groups

Experimental Treatment

Group I: Arm I en vivo Glycolic Index measurementExperimental Treatment1 Intervention

All biopsies are acquired for standard of care and according to standard of care procedures. A 13-gauge biopsy needle and plastic cannula will be inserted into the region of interest identified on MRI and PET. The biopsy needle will be removed, and the Softcell® pH probe, consisting of a 1.8mm diameter high quality glass tip and 1.6m long wire, will be guided down the cannula and inserted at least 15mm into the tissue. Recordings will be made for 1 minute to stabilize the reading, then the pH probe will be removed from the region of interest and placed into a saline vial for the next biopsy target.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor

361 Previous Clinical Trials

27,762 Total Patients Enrolled

National Center for Advancing Translational Sciences (NCATS)NIH

322 Previous Clinical Trials

401,713 Total Patients Enrolled

Benjamin Ellingson, PhDPrincipal InvestigatorUniversity of California at Los Angeles

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this trial currently accepting participants?

"Affirmative. The details available on clinicaltrials.gov point to this clinical trial actively recruiting candidates, which was initially registered on September 6th of 2023 and recently updated on October 24th of the same year. As such, it is looking for 50 participants from a single medical centre."

Answered by AI

Are there a substantial number of participants involved in the trial?

"Affirmative. Research hosted on clinicaltrials.gov verifies that this research trial, first posted in September 6th 2023, is currently enrolling applicants. A total of 50 patients need to be signed up from one medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

2023. "Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06059690.

All > Glioblastoma Long Beach > Brain Tumor